The Shifting Sands of Telehealth: DEA Controlled Substance Compliance and the Rise of Novel Substance Scheduling in 2025-2026

The promise of telehealth to expand access to care has transformed healthcare delivery, but perhaps no area is more fraught with compliance complexities than the remote prescribing of controlled substances. As the healthcare industry moves beyond the Public Health Emergency (PHE) waivers, and regulatory bodies like the Drug Enforcement Administration (DEA) solidify their long-term stances, providers face a rapidly evolving framework. Compounding this challenge is the emergence of novel psychoactive substances (NPS) that present new dilemmas for federal and state scheduling, demanding an unparalleled level of vigilance from healthcare businesses. Navigating this confluence of factors is not merely a legal exercise; it is fundamental to patient safety, operational integrity, and financial viability for any practice engaging in telehealth.

> For more on this topic, see our analysis: [CPOM Unpacked: Deconstructing Corporate Practice of Medicine Risks for National Healthcare Expansion](/blog/cpom-risks-national-healthcare-expansion-2025).

The Evolving Landscape of Controlled Substance Prescribing via Telehealth

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 remains the bedrock of federal controlled substance prescribing via telehealth. It generally requires an in-person medical evaluation before a controlled substance can be prescribed, with specific exceptions. The PHE dramatically expanded one such exception, allowing providers to prescribe controlled substances via telehealth without a prior in-person visit under specific circumstances. As these waivers expire, the DEA has been deliberating its permanent position, publishing proposed rules (RIN 1117-AB85 and RIN 1117-AB86) that have been subject to intense public comment and subsequent delays. While definitive final rules are still pending, the direction is clear: a return to a more stringent regulatory environment than the PHE era, likely emphasizing a significant in-person component or a robust initial telehealth evaluation with clear guardrails.

> For more on this topic, see our analysis: [Navigating the Pine Tree State: A Deep Dive into Maine's Healthcare Compliance Landscape](/blog/maine-healthcare-compliance-landscape).

This federal uncertainty is further complicated by a patchwork of state laws that often impose additional, stricter requirements. For instance, states like Texas (22 TAC 174.6) and Florida (Rule 64B8-9.014) have traditionally maintained conservative stances on telehealth prescribing of controlled substances, particularly certain Schedule II medications. California, too, has specific guidelines through its Medical Board that require robust patient evaluations and documentation for such prescribing. Any practice operating across state lines must contend with this complex matrix, where the least permissive state law often dictates the highest common denominator of compliance.

The Emerging Challenge: Novel Psychoactive Substances (NPS) and Scheduling

The regulatory environment is not static; it is constantly reacting to new pharmacological developments. A critical, and often overlooked, dimension of controlled substance compliance is the rapid emergence and potential scheduling of NPS. These substances, sometimes marketed as

Further Reading

• [CPOM Unpacked: Deconstructing Corporate Practice of Medicine Risks for National Healthcare Expansion](/blog/cpom-risks-national-healthcare-expansion-2025)
• [Navigating the CPOM Minefield: Multi-State Compliance for Modern Healthcare Enterprises (2025-2026 Outlook)](/blog/cpom-minefield-multi-state-compliance)
• [Beyond Borders: Navigating the Corporate Practice of Medicine (CPOM) in a Multi-State Healthcare Landscape, 2025-2026](/blog/cpom-multi-state-healthcare-2025-2026)
• [Navigating the Pine Tree State: A Deep Dive into Maine's Healthcare Compliance Landscape](/blog/maine-healthcare-compliance-landscape)